设为首页收藏本站

中国病毒学论坛|我们一直在坚持!

 找回密码
 立即注册

QQ登录

只需一步,快速开始

搜索
热搜: 活动 交友 discuz
查看: 1021|回复: 1
打印 上一主题 下一主题

宿主IL28B基因型联合病毒基因型对慢性丙型肝炎抗病毒疗效的预测

[复制链接]

1210

帖子

614

学分

1996

金币

论坛区长

Rank: 9Rank: 9Rank: 9Rank: 9

积分
614
跳转到指定楼层
楼主
发表于 2015-8-30 10:46:58 | 只看该作者 回帖奖励 |正序浏览 |阅读模式
原帖由bjlichuan发表于 2011-3-30 16:27;


摘要:目的 综合分析宿主IL28B基因型和丙型肝炎病毒(HCV)基因型对慢性丙型肝炎患者聚乙二醇干扰素联合利巴韦林抗病毒治疗疗效的影响。 方法 对120例慢性丙型肝炎患者进行全程联合治疗,其中92例患者完成了治疗后24周随访,同时分析HCV基因型及宿主IL28B基因型对治疗结束时应答(ETR)及持续病毒学应答(SVR)的影响。 结果 IL28B基因CC型在这组慢性丙型肝炎患者中占89%。在HCV基因1b型患者中,IL28B基因CC 型患者可以获得比非CC(N-CC)型更高ETR率(P=0.0014)和SVR率(P=0.0007),但在HCV基因非1b(N-1b)型患者中,CC型与N-CC型患者间的抗病毒疗效差异无统计学意义;在IL28B基因N-CC型患者中,HCV基因N-1b可以获得比1b型更高的ETR 率(P=0.0350)和SVR率(P=0.0222),但在CC型患者中,HCV基因N-1b与1b型间的疗效差异无统计学意义。 结论 HCV基因型及宿主IL28B基因型对我国慢性丙型肝炎患者聚乙二醇干扰素联合利巴韦林抗病毒治疗疗效具有重要影响。联合检测宿主IL28B基因型和病毒基因型可以更加科学、准确地预测抗病毒疗效,为真正实现个体化治疗提供依据。
分享到:  QQ好友和群QQ好友和群 QQ空间QQ空间 腾讯微博腾讯微博 腾讯朋友腾讯朋友
收藏收藏 分享分享 支持支持 反对反对

1210

帖子

614

学分

1996

金币

论坛区长

Rank: 9Rank: 9Rank: 9Rank: 9

积分
614
沙发
 楼主| 发表于 2015-8-30 10:53:00 | 只看该作者
yaoming发表于 2011-3-30 21:35:
这是HCV研究的一个热点。只是可惜研究得不深入!

请看一下文章:

Results: 1 to 20 of 68

1.IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C.
Fattovich G, Covolo L, Bibert S, Askarieh G, Lagging M, Clément S, Malerba G, Pasino M, Guido M, Puoti M, Gaeta GB, Santantonio T, Raimondo G, Bruno R, Bochud PY, Donato F, Negro F; on behalf of the ITAHEC Study Group.

Aliment Pharmacol Ther. 2011 Mar 28. doi: 10.1111/j.1365-2036.2011.04635.x. [Epub ahead of print]

PMID:21443535[PubMed - as supplied by publisher]
Related citations

2.IL28B single nucleotide polymorphisms in the treatment of hepatitis C.

Lange CM, Zeuzem S.

J Hepatol. 2011 Mar 24. [Epub ahead of print]

PMID:21440591[PubMed - as supplied by publisher]
Related citations

3.High-Dose Pegylated Interferon Alfa and Ribavirin in Non-responder Hepatitis C Patients and Relationship with IL28B Genotype (SYREN Trial).Chevaliez S, Hézode C, Soulier A, Costes B, Bouvier-Alias M, Rouanet S, Foucher J, Bronowicki JP, Tran A, Rosa I, Mathurin P, Alric L, Leroy V, Couzigou P, Mallat A, Charaf-Eddine M, Babany G, Pawlotsky JM.

Gastroenterology. 2011 Mar 23. [Epub ahead of print]

PMID:21439960[PubMed - as supplied by publisher]
Related citations

4.[Treatment of hepatitis C virus in HIV-positive patients.]
Mallolas Masferrer J, Martínez-Rebollar M, Laguno Centeno M.

Gastroenterol Hepatol. 2011 Mar 22. [Epub ahead of print] Spanish.

PMID:21435743[PubMed - as supplied by publisher]
Related citations

5.Treatment of acute HCV infection.
Grebely J, Matthews GV, Dore GJ.

Nat Rev Gastroenterol Hepatol. 2011 Mar 22. [Epub ahead of print]

PMID:21423258[PubMed - as supplied by publisher]
Related citations

6.[Genetics and hepatitis C treatment: towards a personalized treatment?]
Lens García S, Coto-Llerena M, Pérez Del Pulgar Gallart S, Forns Bernhardt X.

Gastroenterol Hepatol. 2011 Mar 18. [Epub ahead of print] Spanish.

PMID:21420759[PubMed - as supplied by publisher]
Related citations

7.Genetic variation in IL28B with respect to vertical transmission of hepatitis C virus and spontaneous clearance in HCV infected children.

Ruiz-Extremera A, Muñoz-Gámez J, Salmerón-Ruiz MA, de Rueda PM, Quiles-Pérez R, Gila-Medina A, Casado J, Martín AB, Sanjuan-Nuñez L, Carazo A, Pavón EJ, Ocete-Hita E, León J, Salmerón J.

Hepatology. 2011 Mar 16. doi: 10.1002/hep.24298. [Epub ahead of print]

PMID:21413051[PubMed - as supplied by publisher]
Related citations

8.Innate immune genes synergize to predict increased risk of chronic disease in hepatitis C virus infection.

Dring MM, Morrison MH, McSharry BP, Guinan KJ, Hagan R; Irish HCV Research Consortium, O'Farrelly C, Gardiner CM.

Proc Natl Acad Sci U S A. 2011 Mar 14. [Epub ahead of print]

PMID:21402922[PubMed - as supplied by publisher]
Related citations

9.Portal Pressure Predicts Outcome and Safety of Antiviral Therapy in Cirrhotic Patients with HCV infection.
Reiberger T, Rutter K, Ferlitsch A, Payer BA, Hofer H, Beinhardt S, Kundi M, Ferenci P, Gangl A, Trauner M, Peck-Radosavljevic M.

Clin Gastroenterol Hepatol. 2011 Mar 10. [Epub ahead of print]

PMID:21397726[PubMed - as supplied by publisher]
Related citations

10.Response Prediction in Chronic Hepatitis C by Assessment of IP-10 and IL28B-Related Single Nucleotide Polymorphisms.

Lagging M, Askarieh G, Negro F, Bibert S, Söderholm J, Westin J, Lindh M, Romero A, Missale G, Ferrari C, Neumann AU, Pawlotsky JM, Haagmans BL, Zeuzem S, Bochud PY, Hellstrand K; for the DITTO-HCV Study Group.

PLoS One. 2011 Feb 24;6(2):e17232.

PMID:21390311[PubMed - as supplied by publisher] Free PMC Article
Free full text Related citations

11.Association between IL28B gene polymorphisms and plasma HCV-RNA levels in HIV/HCV-co-infected patients.
Labarga P, Soriano V, Caruz A, Poveda E, Di Lello F, Hernandez-Quero J, Moreno S, Bernal E, Miró JM, Leal M, Gutierrez F, Portilla J, Pineda JA; on behalf of CoRIS.

AIDS. 2011 Mar 27;25(6):761-766.

PMID:21378537[PubMed - as supplied by publisher]
Related citations

12.Coffee Consumption is Associated with Response to Peginterferon and Ribavirin Therapy in Patients with Chronic Hepatitis C.

Freedman ND, Curto TM, Lindsay KL, Wright EC, Sinha R, Everhart JE; HALT-C Trial Group.

Gastroenterology. 2011 Mar 1. [Epub ahead of print]

PMID:21376050[PubMed - as supplied by publisher]
Related citations

13.IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection.
Moghaddam A, Melum E, Reinton N, Ring-Larsen H, Verbaan H, Bjøro K, Dalgard O.

Hepatology. 2011 Mar;53(3):746-54. doi: 10.1002/hep.24154.

PMID:21374656[PubMed - in process]
Related citations

14.Estimating the net contribution of IL28B variation to spontaneous hepatitis C virus clearance.

di Iulio J, Ciuffi A, Fitzmaurice K, Kelleher D, Rotger M, Fellay J, Martinez R, Pulit S, Furrer H, Günthard HF, Battegay M, Bernasconi E, Schmid P, Hirschel B, Barnes E, Klenerman P, Telenti A, Rauch A; the Swiss HIV Cohort Study.

Hepatology. 2011 Feb 28. doi: 10.1002/hep.24263. [Epub ahead of print]

PMID:21360716[PubMed - as supplied by publisher]
Related citations

15.Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b.Sakamoto N, Nakagawa M, Tanaka Y, Sekine-Osajima Y, Ueyama M, Kurosaki M, Nishida N, Tamori A, Yuki NS, Itsui Y, Azuma S, Kakinuma S, Hige S, Itoh Y, Tanaka E, Hiasa Y, Izumi N, Tokunaga K, Mizokami M, Watanabe M; the Ochanomizu-Liver Conference Study Group.

J Med Virol. 2011 May;83(5):871-878. doi: 10.1002/jmv.22038. Epub 2011 Feb 25.

PMID:21360545[PubMed - as supplied by publisher]
Related citations

16.HCV-GenoFibrotest: A combination of viral, liver and genomic (IL28b, ITPA, UGT1A1) biomarkers for predicting treatment response in patients with chronic hepatitis C.Costa JM, Telehin D, Munteanu M, Kobryn T, Ngo Y, Thibault V, Joseph M, Ratziu V, Benhamou Y, Koz'ko V, Dubins'ka G, Poveda JD, Poynard T.

Clin Res Hepatol Gastroenterol. 2011 Feb 25. [Epub ahead of print]

PMID:21354889[PubMed - as supplied by publisher]
Related citations

17.IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C.
Bochud PY, Bibert S, Negro F, Haagmans B, Soulier A, Ferrari C, Missale G, Zeuzem S, Pawlotsky JM, Schalm S, Hellstrand K, Neumann AU, Lagging M; the DITTO-HCV study group.

J Hepatol. 2011 Feb 24. [Epub ahead of print]

PMID:21354446[PubMed - as supplied by publisher]
Related citations

18.IL28B genetic variations are associated with high sustained virological response (SVR) of interferon-α plus ribavirin therapy in Taiwanese chronic HCV infection.

Chen JY, Lin CY, Wang CM, Lin YT, Kuo SN, Shiu CF, Chang SW, Wu J, Sheen IS.

Genes Immun. 2011 Feb 24. [Epub ahead of print]

PMID:21346780[PubMed - as supplied by publisher]
Related citations

19.Prospects for personalizing antiviral therapy for hepatitis C virus with pharmacogenetics.Tavis JE, Donlin MJ, Aurora R, Fan X, Di Bisceglie AM.

Genome Med. 2011 Feb 8;3(2):8. [Epub ahead of print]

PMID:21345258[PubMed - as supplied by publisher]
Related citations

20.Amino Acid Substitution in HCV Core Region and Genetic Variation near the IL28B Gene Affect Viral Dynamics during Telaprevir, Peginterferon and Ribavirin Treatment.Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Chayama K, Nakamura Y, Kumada H.

Intervirology. 2011 Feb 16. [Epub ahead of print]

PMID:21325786[PubMed - as supplied by publisher]
Related citations
您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

QQ|论坛App下载|Archiver|小黑屋|中国病毒学论坛    

GMT+8, 2024-11-23 18:35 , Processed in 0.074069 second(s), 28 queries .

Powered by Discuz! X3.2

© 2001-2013 Comsenz Inc.

快速回复 返回顶部 返回列表